Trimethadione is an anticonvulsant agent indicated for the control of treatment-refractory petit mal seizures. An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity.
- Mechanism
- Curator reviewed
Dione anticonvulsants reduce T-type calcium currents in thalamic neurons, including thalamic relay neurons. It does so via the inhibition of voltage dependent T-type calcium channels. This raises the threshold for repetitive activity in the thalamus, and inhibits corticothalamic transmission. Thus, the abnormal thalamocortical rhythmicity, which is thought to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram(EEG) with absence seizures, is dampened.
- Primary indication
- Used in the control of absence (petit mal) seizures that are refractory to treatment with other medications.Curator reviewed
- Formula / weight
- C6H9NO3 · 143.1406 g/mol (avg)
- First approval
- United States, 1946
- Also known as
- Trimethadion · Troxidone
- Code names
- A 2297 · J2.519D · NSC-15799 · NSC-169503
Resolves to
IRYJRGCIQBGHIV-UHFFFAOYSA-NSMILESCN1C(=O)OC(C)(C)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Trimethadione, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account